8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2020 / Double-blind, randomized crossover trial
In two study parts, healthy lean men received intragastric quinine (275 mg or 600 mg) or control 30 minutes before a mixed-nutrient drink (part A, n=15) or a buffet meal (part B, n=12). Alone, both doses modestly stimulated insulin (P < 0.05). Following the drink, both quinine doses reduced plasma glucose and stimulated insulin (P < 0.05); 275 mg stimulated GLP-1 (P < 0.05), while 600 mg showed a trend toward stimulating GLP-1 (P = 0.066) and glucagon (P = 0.073). Quinine did not alter gastric emptying of the nutrient drink or subsequent buffet energy intake.
Bitarafan V, Fitzgerald PCE, Little TJ, et al. Am J Physiol Regul Integr Comp Physiol, 2020. PMID 31774306
2020 / Crossover feeding trial
Thirteen healthy young men consumed a control diet for 2 weeks followed by 5 days of an isocaloric high-fat diet (HFD; 55% fat, 25% saturated). Intestinal permeability and responses to a high-fat meal challenge were evaluated before and after the HFD. Intestinal permeability was not affected by the HFD (p > 0.05), but fasting endotoxin increased two-fold (p = 0.04). Skeletal muscle glucose and fatty acid oxidation increased post-meal before the HFD (+97% and +106%) but decreased post-meal after the HFD (-24% and +16%, respectively), while insulin sensitivity remained unchanged.
Bowser SM, McMillan RP, Boutagy NE, et al. Metabolism, 2020. PMID 31785256
2020 / Randomized double-blind placebo-controlled pilot trial
In a 12-week pilot trial, 24 adults with obesity and mild-moderate insulin resistance were randomized to weekly oral FMT capsules from healthy lean donors or placebo for 6 weeks. There were no statistically significant improvements in insulin sensitivity between groups (+5% ± 12% in FMT vs -3% ± 32% in placebo, mean difference 9%, 95% CI -5% to 28%, p = 0.16). Additionally, no significant differences were seen for HOMA-IR (mean difference 0.2, 95% CI -0.9 to 0.9, p = 0.96), lean mass (mean difference -0.1 kg, p = 0.87), or fat mass (mean difference 1.2 kg, p = 0.18). Variable bacterial engraftment persisted throughout 12 weeks with no serious adverse events related to FMT.
Yu EW, Gao L, Stastka P, et al. PLoS Med, 2020. PMID 32150549
2020 / Randomized, double-blinded, placebo-controlled, crossover trial
In a randomized, double-blinded, placebo-controlled crossover study, 13 healthy overweight or obese adults received 1000 mg/d nicotinamide riboside (NR) and placebo for 6 weeks each. NR increased skeletal muscle markers of NAD+ synthesis, body fat-free mass (62.65% ± 2.49% vs 61.32% ± 2.58%; change: 1.34% ± 0.50%, P = 0.02), and sleeping metabolic rate. Skeletal muscle acetylcarnitine concentrations increased (4558 ± 749 vs 3025 ± 316 pmol/mg dry weight; change: 1533 ± 683, P = 0.04), along with exercise acetylcarnitine-forming capacity (P = 0.01). However, NR had no effects on insulin sensitivity, mitochondrial function, hepatic/intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, blood pressure, inflammation markers, or energy metabolism.
Remie CME, Roumans KHM, Moonen MPB, et al. Am J Clin Nutr, 2020. PMID 32320006
2020 / Two-period randomized crossover trial
In a randomized crossover trial, 55 adults with elevated BMI and cardiometabolic risk consumed 3/4 cup/day of mixed dried fruits (plums, figs, dates, raisins) or an isocaloric, carbohydrate-matched control snack for 4 weeks. Lipid and lipoprotein concentrations did not differ between conditions, though dried fruit increased LDL-cholesterol from baseline (0.10 mmol/l, 95% CI 0.01, 0.20). Compared with control, dried fruit increased mean fasting glucose (0.08 mmol/l, 95% CI 0.005, 0.16; P = 0.038), while vascular outcomes, fasting insulin, and C-reactive protein did not differ. Mean weight changes did not differ between groups (P = 0.55), but tended to increase in both.
Sullivan VK, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 32513313
2020 / Randomized, placebo-controlled study
Participants were randomized to wear a novel nasal device for 5-12 hours daily or receive daily saline nasal drops, alongside a 500 kcal/day reduced diet for 12 weeks. Sense of smell decreased from 6.4 ± 0.9 to 4.4 ± 1.5 in the device group (p < 0.001) with no change in controls. Overall weight loss was 6.6 ± 3.7% in the device group versus 5.7 ± 3.5% in controls (between-group p > 0.05), but was significantly greater with the device among participants aged ≤50 years (7.7 ± 4.2% vs. 4.1 ± 2.9%, p = 0.02). The device group also showed significant reductions in insulin, HOMA-IR, and preferences for sugar, sweet beverages, and artificial sweeteners.
Dicker D, Beck A, Markel A, et al. Obes Facts, 2020. PMID 32950989
2020 / Three-phase sequential intervention study
Thirty adolescents with type 1 diabetes completed three 1-week phases: Phase I with a standard diet, followed by Phase II adding oat flakes with 3 g/day beta-glucan, and Phase III adding oat flakes with 6 g/day beta-glucan. Maximal, mean, daytime, and night blood glucose levels were lowest at Phase III, while minimal blood glucose was highest at Phase III (p < 0.05). Premeal, postmeal, and peak blood glucose values were lowest at Phase III for breakfast, lunch, and overall, with delayed peak times (p < 0.05). Phase III also significantly reduced glycemic variability metrics including SD, CV, LBGI, and CONGA compared to Phase I or II (p < 0.05), while durations in hypoglycemia, euglycemia, and hyperglycemia did not differ significantly between phases.
Bozbulut R, Şanlıer N, Döğer E, et al. Diabetes Res Clin Pract, 2020. PMID 32971156
2019 / Crossover trial
Researchers evaluated postprandial glucose and insulin responses to an oral glucose tolerance test (OGTT at 0800h vs 2000h, n=10) and a low GI meal consumed at 0800h, 2000h, and 0000h (n=9). In the OGTT, glucose iAUC was higher in the evening than morning (p=0.007). Following the low GI meal, glucose iAUC was higher at evening and midnight compared to morning (p=0.008, p=0.021), with no significant difference between evening and midnight (p=0.594). Insulin iAUC was also significantly higher at evening and midnight compared to morning (p=0.008 for both).
Leung GKW, Huggins CE, Bonham MP Clin Nutr, 2019. PMID 29248250
2019 / Randomized open-label crossover trial
Fifteen patients with uncontrolled type 2 diabetes participated in a randomized, open-label crossover study receiving either two days of oatmeal or a diabetes-adapted diet during a 5-day hospital stay. Oatmeal significantly reduced required insulin doses on days 3 and 4 compared to day 2 (82.0±30.3 and 69.9±29.9 IU vs. 112±36.2 IU; P<0.001), whereas insulin requirements did not change during the control period. Mean blood glucose and fasting glucose changes did not differ significantly between treatments, but HbA1c was lower four weeks after the oatmeal intervention.
Delgado G, Kleber ME, Krämer BK, et al. Exp Clin Endocrinol Diabetes, 2019. PMID 30157531
2019 / Multicenter, randomized, double-blind, placebo-controlled trial
A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).
Bhatt DL, Steg PG, Miller M, et al. N Engl J Med, 2019. PMID 30415628
2019 / Double-blind randomized controlled trial
Older adults underwent 12 weeks of aerobic exercise training (AET) while randomized double-blind to placebo (n = 26) or metformin (n = 27). Independent of treatment, AET decreased fat mass, HbA1c, fasting plasma insulin, 24-hr ambulant mean glucose, and glycemic variability. However, metformin attenuated improvements in whole-body insulin sensitivity and VO2 max, and abrogated increases in skeletal muscle mitochondrial respiration. Mitochondrial protein synthesis rates were not different between treatments.
Konopka AR, Laurin JL, Schoenberg HM, et al. Aging Cell, 2019. PMID 30548390
2019 / Three-group randomized crossover trial
Researchers evaluated the acute effects of two energy- and macronutrient-matched meals—a vegan meal with tofu (V-meal) versus a processed-meat and cheese meal (M-meal)—in men with type 2 diabetes, obese men, and healthy men (n=20 each). Postprandial GLP-1 secretion increased after the V-meal in diabetic men (by 30.5%) and healthy men (by 15.8%), while amylin increased across all groups (diabetic by 15.7%, obese by 11.5%, healthy by 13.8%). Postprandial PYY increased significantly only in healthy men (by 18.9%). Satiety was higher after the V-meal in all groups: by 9% in diabetic, 18.7% in obese, and 25% in healthy men.
Klementova M, Thieme L, Haluzik M, et al. Nutrients, 2019. PMID 30642053
2019 / Single-blinded randomized controlled trial
In a 12-week single-blinded trial, 77 constipated patients with type 2 diabetes received cookies containing 10 g flaxseed, 10 g psyllium, or placebo twice daily. Compared to placebo, both flaxseed and psyllium groups showed significant improvements from baseline in constipation symptoms (P = 0.002), stool consistency (P < 0.001), weight (P < 0.001), BMI (P < 0.001), fasting plasma glucose (P = 0.004), cholesterol (P = 0.010), LDL cholesterol (P = 0.031), and cholesterol/HDL cholesterol ratio (P = 0.019). Flaxseed appeared superior to psyllium for improving these markers, and no adverse effects were observed.
Soltanian N, Janghorbani M Clin Nutr ESPEN, 2019. PMID 30661699
2019 / Randomized crossover trial
In a randomized crossover study of obese adults with type 2 diabetes, acute raspberry intake lowered postprandial serum glucose at two and four hours and decreased IL-6 and hsTNF-alpha at four hours (p < 0.05). Following four weeks of daily supplementation, IL-6 and hsTNF-alpha remained significantly reduced compared to control periods (p < 0.05). The intervention did not alter fasting blood sugar, blood lipids, C-reactive protein, or vascular elasticity.
Schell J, Betts NM, Lyons TJ, et al. Ann Nutr Metab, 2019. PMID 30763939
2019 / Randomized crossover trial
In a randomized crossover trial of 20 participants with type 2 diabetes, researchers compared postprandial responses to an energy- and macronutrient-matched standard meat meal versus a vegan meal. Postprandial glucose responses were similar between meals (p = 0.64). However, the vegan meal increased stimulated secretion of insulin (by 30.5%), C-peptide (by 7.1%), amylin (by 15.7%), and GLP-1 (by 19.2%, all p < 0.001), while GIP decreased by -9.4% (p = 0.02). Parameters of beta-cell function also increased after the vegan meal.
Kahleova H, Tura A, Klementova M, et al. Nutrients, 2019. PMID 30813546
2019 / Cross-sectional comparison and short-term dietary intervention
Researchers studied dietary methionine restriction in mice and evaluated circulating FGF21 levels in humans following different diets. In humans, plasma FGF21 levels were markedly higher in vegans compared with omnivores, and circulating FGF21 increased significantly in omnivores after 4 days on a vegetarian diet. In NZO mice, a 9-week methionine-restricted diet elevated plasma FGF21, increased insulin sensitivity, raised energy expenditure, and prevented hyperglycemia without altering food intake or fat mass.
Castaño-Martinez T, Schumacher F, Schumacher S, et al. FASEB J, 2019. PMID 30841758
2019 / Randomized controlled trial
Thirty-four males with type 2 diabetes were randomized to a resistance training group (RTG, n=12), an aerobic training group (ATG, n=11), or a control group (n=11) for 8 weeks. Both ATG and RTG significantly decreased serum fetuin-A and fetuin-B (p < 0.05) and increased FGF-21 (p < 0.05). Compared to ATG, the RTG showed a greater decrease in fetuin-A (-18.3% vs. -7.9%) and fetuin-B (-29.2% vs. -11.45%), and a lower increase in FGF-21 (42.2% vs. 25.1%), respectively.
Keihanian A, Arazi H, Kargarfard M Physiol Int, 2019. PMID 30888221
2019 / Randomized crossover clinical trial
In a randomized crossover trial, 49 prediabetic subjects consumed an isocaloric control diet or a pistachio-supplemented diet (including 57 g pistachios/d) for 4 months each, separated by a 2-week washout. Compared with the control diet, the pistachio diet reduced oxidative damage to DNA (mean: -3.5%; 95% CI: -8.07%, 1.05%; P = 0.009). It also significantly upregulated expression of TERT (164%, P = 0.043) and WRAP53 (53%, P = 0.001). Changes in TERT expression were negatively correlated with changes in fasting plasma glucose and HOMA-IR.
Canudas S, Hernández-Alonso P, Galié S, et al. Am J Clin Nutr, 2019. PMID 31051499
2019 / Randomized, parallel, controlled trial
Sixty-six patients with NAFLD were randomly assigned to a 500-calorie deficit diet either with or without 240 ml/day of soy milk for 8 weeks. Compared to the control group, the soy milk group showed significantly greater reductions in serum insulin (-3.44 ± 5.02 vs. -1.09 ± 3.77 μIU/ml, P = 0.04), HOMA-IR (-0.45 ± 0.64 vs -0.14 ± 0.47, P = 0.03), systolic BP (-3.81 ± 4.15 vs -1.48 ± 2.93 mmHg, P = 0.01), and diastolic BP (-2.39 ± 2.80 vs. -0.94 ± 2.76 mmHg, P = 0.04), plus a significant increase in QUICKI (0.02 ± 0.032 vs. 0.008 ± 0.018, P = 0.04). Changes in fasting blood sugar, HOMA-β%, fibrinogen, and malondialdehyde did not differ significantly between groups.
Maleki Z, Jazayeri S, Eslami O, et al. Complement Ther Med, 2019. PMID 31126574
2019 / Randomized controlled trial
The Women's Health Initiative Dietary Modification trial randomized 48,835 postmenopausal women to either a low-fat dietary pattern intervention (reducing fat to 20% of energy and increasing vegetables, fruit, and grains) or a usual-diet comparison group. Time-to-outcome analyses showed no significant differences for invasive breast cancer, colorectal cancer, or coronary heart disease (CHD) over an 8.5-year median intervention or longer-term follow-up. However, over a 19.6-year median follow-up, the intervention group had significantly lower hazards for breast cancer followed by death (HR 0.84; 95% CI: 0.74, 0.96) and diabetes requiring insulin (HR 0.87; 95% CI: 0.77, 0.98), along with other benefits related to breast cancer, CHD, and diabetes without adverse effects.
Prentice RL, Aragaki AK, Howard BV, et al. J Nutr, 2019. PMID 31175807
2019 / Pilot study
A pilot study evaluated the postprandial effects of high-fat/high-glycemic load meals enriched with blueberries in 5 obese/overweight patients with metabolic syndrome. Significant decreases in urinary methylamines, acetoacetate, acetone, and succinate were observed at 2 and 4 hours post-ingestion, alongside accumulation of gut-derived phenolic acids. In mononuclear blood cells, mRNA expression of interleukin-6 significantly decreased and transforming growth factor-β significantly increased following blueberry supplementation.
Sobolev AP, Ciampa A, Ingallina C, et al. Metabolites, 2019. PMID 31295937
2019 / Randomized double-blind placebo-controlled trial
In a randomized, double-blind trial, patients with type 2 diabetes and CVD received 360 µg/day menaquinone-7 (MK-7, n=35) or placebo (n=33) for 6 months. Target-to-background ratio (TBR) on 18F-NaF PET scans tended to increase in the MK-7 group compared to placebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), but the change was not significant. Log-transformed CT calcification mass did not significantly differ between groups (0.50; 95% CI: -0.23, 1.36; P = 0.18). MK-7 supplementation significantly decreased dp-ucMGP compared with placebo (-205.6 pmol/L; 95% CI: -255.8, -155.3 pmol/L), and no adverse events occurred.
Zwakenberg SR, de Jong PA, Bartstra JW, et al. Am J Clin Nutr, 2019. PMID 31387121
2019 / 12-week randomized, double-blind, placebo-controlled parallel-group trial
A 12-week randomized, double-blind, placebo-controlled trial evaluated the effects of nicotinamide riboside (NR; 1000 mg twice daily, n = 20) versus placebo (n = 20) in 40 males with obesity and insulin resistance. Supplementation with NR did not affect fasting or postchallenge levels of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Furthermore, no changes in circulating adipsin or bile acids were observed.
Dollerup OL, Trammell SAJ, Hartmann B, et al. J Clin Endocrinol Metab, 2019. PMID 31390002
2019 / Randomized clinical trial
In this randomized clinical trial, 43 patients with type 2 diabetes and chronic periodontitis were randomly allocated to receive resveratrol supplements or placebo for 4 weeks alongside non-surgical periodontal therapy. In the intervention group, the mean serum level of IL6 decreased significantly post-intervention from 2.19 ± 1.09 to 1.58 ± 1.06 (P = 0.039). However, no significant differences were observed between the intervention and control groups post-intervention for IL6, TNFα, TAC, or CAL.
Javid AZ, Hormoznejad R, Yousefimanesh HA, et al. Diabetes Metab Syndr, 2019. PMID 31405706